$SCYX

SCYNEXIS INC

No enriched coverage for $SCYX in the last 7 days.

No SEC Form 4 filings for $SCYX in the last 30 days.

Low

SCYNEXIS (NASDAQ: SCYX) seeks approval for reverse stock split

SCYNEXIS (NASDAQ: SCYX) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-10 to maintain its listing on The Nasdaq Capital Market. The virtual special meeting is scheduled for May 19, 2026, where shareholders will vote on the proposal to increase the per-share price and avoid potential delisting proceedings by June 15, 2026. If approved, the board will have the discretion to determine the exact ratio and implement the split, which will proportionally reduce outstanding shares and adjust equity incentive plans.

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

JERSEY CITY, N.J., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing ...